Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Friday, December 5, 2008

A word from Dr. Richard S. Lord, PhD: of Metametrix

Richard S. Lord, PhD, director of the Department of Science and Education at Metametrix Clinical Laboratory, has helpfully posted a reply to the post on his 'GIfx' presentation video posted in this blog recently. At the moment (until someone investigates), it seems likely gut dysbiosis may be a factor (or the factor) in some metabolic body odor cases, especially the fecal/gas/sewage/garbage/rotten egg/etc type that seems the most common type. Metametrix specialise in gut dysbiosis testing, and other metabolic types of testing. Thank you from the community Dr Lord, for taking the time to post.

Metametrix GIfx test will likely give society the best definition of 'dysbiosis(es)' yet, and the most up-to-date understanding of gut ecology so far, although the test has not been available that long, so it is very early days. They detect the state of the gut ecology using DNA detection of microbes in stool samples. This will likely become the standard way to test stool samples for microbiota evaluation. The old fashioned way, still probably commonly used, meant having to 'culture' microbes from stool samples in the lab. The advantages of DNA testing are explained on the GIfx site

Having noticed this new posting of the presentation, I can add that a publication is now being prepared to report our finding of distinct groupings of predominant genera among the patient stool specimens that have been examined. Specific genera tend to appear at high levels as one of three clusters. When any one of the clusters dominates the fecal bacteria population, higher incidences of opportunistic bacteria are found. This finding represents another step in the unfolding story of what specific patterns constitute states of dysbiosis.

From routine clinical evaluations of patients, we are amassing a very large database of results using the DNA-based methods to analyze stool specimens. Doctors who use the testing are learning how to evaluate the significance of each abnormality (such as the presence of a parasite of pathogen) in relation to the total picture, including the balance of predominant anaerobic bacteria.
This is an exciting time for scientist and clinicians who have long sought to understand how the billions of microbes that live within us contribute to human health and disease. Stay tuned as the story continues to unfold.

Richard Lord

0 comments:

Post a Comment